Generic drug
Homatropine / hydrocodone price, strengths & recalls
Pharmacies pay $28.08 for 30 tablets of Homatropine / hydrocodone 1.5 mg / 5 mg tablet this week, and from $28.08 to $49.35 across its 2 priced strengths and forms. 5 manufacturers make it. It has 3 recalls on record, none ongoing. Its official label last changed on August 27, 2026.
Generic- Fair cash price
- $42.79
- Strengths
- 2
- Makers
- 5
- Updated
- Nov 11
Homatropine / hydrocodone price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 0.3 mg/mL / 1 mg/mL oral solution | $0.1043 | $49.35 / 473 mL |
| 1.5 mg / 5 mg tablet | $0.9360 | $28.08 / 30 tablets |
Supply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Homatropine / hydrocodone
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE safely and effectively. See full prescribing information for HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE. HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE tablets, for oral use, CII Initial U.S. Approval: 1943
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME
Addiction, Abuse, and Misuse
Hydrocodone bitartrate and homatropine methylbromide exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Reserve hydrocodone bitartrate and homatropine methylbromide for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough has been made. Assess each patient's risk prior to prescribing hydrocodone bitartrate and homatropine methylbromide, prescribe hydrocodone bitartrate and homatropine methylbromide for the shortest duration that is consistent with individual patient treatment goals, monitor all patients regularly for the development of addition or abuse, and refill only after reevaluation of the need for continued treatment
[see Warnings and Precautions (5.1)].
Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with use of hydrocodone bitartrate and homatropine methylbromide. Monitor for respiratory depression, especially during initiation of hydrocodone bitartrate and homatropine methylbromide therapy or when used in patients at higher risk
[see Warnings and Precautions (5.2)].
Accidental Ingestion
Accidental ingestion of even one dose of hydrocodone bitartrate and homatropine methylbromide, especially by children, can result in a fatal overdose of hydrocodone
[see Warnings and Precautions (5.2)].
Risk of Medication Errors
Ensure accuracy when prescribing, dispensing, and administering hydrocodone bitartrate and homatropine methylbromide. Dosing errors can result in accidental overdose and death. Always use an accurate milliliter measuring device when measuring and administering hydrocodone bitartrate and homatropine methylbromide
[see Dosage and Administration (2.1), Warnings and Precautions (5.5)].
Cytochrome P450 3A4 Interaction
The concomitant use of hydrocodone bitartrate and homatropine methylbromide with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. Avoid the use of hydrocodone bitartrate and homatropine methylbromide in patients taking a CYP3A4 inhibitor or inducer
[see Warnings and Precautions (5.7), Drug Interactions (7.2, 7.3)].
Risks From Concomitant Use With Benzodiazepines or Other CNS Depressants
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Avoid the use of hydrocodone bitartrate and homatropine methylbromide in patients taking benzodiazepines, other CNS depressants, or alcohol
[see Warning and Precautions (5.8), Drug Interactions (7.5)]
Interaction with Alcohol
Instruct patients not to consume alcoholic beverages or use prescription or non-prescription products that contain alcohol while taking hydrocodone bitartrate and homatropine methylbromide. The co-ingestion of alcohol with hydrocodone bitartrate and homatropine methylbromide may result in increased plasma levels and a potentially fatal overdose of hydrocodone
[see Warnings and Precautions (5.8) and Drug Interactions (7.1)].
Neonatal Opioid Withdrawal Syndrome
Hydrocodone bitartrate and homatropine methylbromide is not recommended for use in pregnant women
[see Use in Specific Populations (8.1)]. Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery
[see Warnings and Precautions (5.13)].
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE- THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME
See full prescribing information for complete boxed warning.
Hydrocodone bitartrate and homatropine methylbromide exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and monitor closely for these behaviors and conditions. (5.1)
Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially upon initiation or when used in patients at higher risk. (5.2)
Accidental ingestion of hydrocodone bitartrate and homatropine methylbromide, especially by children, can result in a fatal overdose of hydrocodone. (5.2)
Ensure accuracy when prescribing, dispensing, and administering hydrocodone bitartrate and homatropine methylbromide. Dosing errors can result in accidental overdose and death. (2,1, 5.5)
Concomitant use with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of hydrocodone. Avoid the use of hydrocodone bitartrate and homatropine methylbromide in patients taking CYP3A4 inhibitors or inducers. (5.7, 7.2, 7.3)
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Avoid the use of hydrocodone bitartrate and homatropine methylbromide in patients taking benzodiazepines, other CNS depressants, or alcohol. (5.8, 7.4)
Instruct patients not to consume alcohol or any products containing alcohol while taking hydrocodone bitartrate and homatropine methylbromide because co-ingestion can result in fatal plasma hydrocodone levels. (5.8, 7.1)
Hydrocodone bitartrate and homatropine methylbromide is not recommended for use in pregnant women. Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology expert will be available at delivery. (5.13, 8.1)
Recent major changes (as listed on the label)
Boxed Warning | 12/2025 |
Indications and Usage (1) | 12/2025 |
Dosage and Administration (2.3) | 12/2025 |
Warnings and Precautions (5.1, 5.2, 5.8, 5.9) | 12/2025 |
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA005213 · Genus
- First approved
- March 23, 1943 (83 years ago)
- Latest approved change
- December 22, 2025
- Approved label
- PDF, Jan 7, 2026
- Generic makers
- 4 approved generic applications on the market
Homatropine / hydrocodone questions
How much does homatropine / hydrocodone cost without insurance?
Pharmacies pay about $28.08 for 30 tablets of homatropine / hydrocodone 1.5 mg / 5 mg tablet ($0.9360 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $42.79. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is homatropine / hydrocodone in shortage?
No shortage is reported for homatropine / hydrocodone right now. We check the national shortage list every day.
Has homatropine / hydrocodone been recalled?
3 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the homatropine / hydrocodone label last change?
The official label was last updated on August 27, 2026 (version 10). See what changed.
Talk about homatropine / hydrocodone
No comments yet. Questions, tips, what worked for you - start the conversation.